Extension Study of Hetrombopag in Severe Aplastic Anemia
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, placebo-control, phase 3 study of hetrombopag in patients with
treatment-naive severe aplastic anemia. All subjects who have completed or withdrawn from the
HR-TPO-SAA-III study will voluntarily participate in this extension study.
Subjects will receive the same study drug (hetrombopag or placebo) as in study
HR-TPO-SAA-III, with the same doses and administration schedule or with modifications based
on the actual conditions.
The primary objective of this extension study is to give the subjects participating in the
HR-TPO-SAA-III study the continued access to the study drug (hetrombopag or placebo) after
the completion of the HR-TPO-SAA-III study.